MPO and anti-neutrophil cytoplasmic antibody-associated vasculitis: Recently, a study by Antonelou M. et al. showed in an in vivo preclinical model that therapeutic MPO inhibition in a mouse model of ANCA-associated vasculitis reduced neutrophil degranulation, NET formation and kidney damage without increasing adaptive immune responses, suggesting that MPO inhibition may be an effective adjunctive therapy [25].